Nasolabial fold filler or cheek support: what is the actual choice?

A nasolabial fold can be a direct filler target, while a cheek-support plan addresses nearby volume that may affect the fold’s appearance. Neither strategy is automatically better. A small randomized split-face study found similar short-term fold improvement after low-volume cheek or direct fold injection; it cannot identify the best plan for every face, product or longer-term goal. The decision should name the tissue and visual endpoint, then identify an exact product and its approved site.¹²

The fold is the crease running from the side of the nose toward the mouth. It may be visible at rest, deepen with expression, or appear stronger when cheek volume and surrounding skin change. Those observations are different jobs. A consultation should translate “erase my smile lines” into a description of what is being changed and what will remain natural during expression.

Choose the comparison unit before comparing syringes

Direct fold placement and cheek support differ in site, purpose and product. A direct plan places filler along the fold’s contour. A cheek plan adds volume in the midface to change support or shadow, with the fold as a secondary visual endpoint. A combined plan does both, but more treatment is not proof of better value or a better result.

The facial-balancing guide addresses broad multi-feature planning. This decision is narrower: whether a specific fold needs direct correction, whether the cheek is independently part of the goal, and what evidence supports paying for either placement.

What the randomized comparison actually found

The 2014 study randomized split-face use of three hyaluronic-acid techniques: low-volume deep mid-to-lateral cheek placement, direct mid-to-deep fold placement, and both. A blinded investigator assessed wrinkle severity and global improvement after four to six weeks. Each approach improved the measured fold ratings, with no statistically significant difference between techniques. Patients showed a slight preference for the combined approach, which also used the most filler.²

This is useful because it tests the marketing idea that the cheek must always be filled first. It does not support the opposite rule that direct placement is always enough. The study was small, short, and based on specific techniques and products. It cannot establish long-term durability, a universal product volume, the best approach for very different anatomy, or comparative serious-event rates.

Ask a provider to show how the proposed placement connects to the feature that bothers you. A plan that adds cheek filler solely because “everyone needs support” should be able to explain the expected change to the cheek and fold separately. Conversely, a direct fold plan should explain why adding material in that crease is reasonable rather than using a nearby site or another method.

Approved site is a product question

FDA describes absorbable filler approvals for certain facial folds and augmentation of specific areas, including cheeks. That overview does not mean every filler is approved for every site. For instance, Voluma XC’s FDA physician directions identify deep cheek augmentation to correct age-related midface volume deficit in adults over 21. A practitioner proposing it for another location would need to describe the exact intended use and whether it is outside that product’s approved indication.¹³

This distinction applies even if the same material family is mentioned. “Hyaluronic acid” is an ingredient category; the labeled product, concentration, cross-linking, depth, site, and study population matter. Ask to see the named product and patient information rather than assuming that a familiar brand name authorizes any facial map.

The FDA also warns that accidental injection into a blood vessel can cause tissue death, vision abnormalities including blindness, or stroke. Those are uncommon but serious risks. The vascular-warning guide explains the emergency distinction; before booking, the practical question is who performs the injection and how the practice responds to a suspected complication.¹

A useful consultation sketch has four layers

Photograph the right endpoint. Standardized rest and smile views help separate a static fold from normal movement. Lighting and camera angle can make a shadow look like a deeper crease. The plan should identify which view and feature will be reassessed.

Name the tissue. A fold can involve skin, subcutaneous volume, facial movement and midface support. Filler adds volume; it does not remove skin or reproduce a surgical lift. A discussion that describes every fold as “volume loss” may miss a different mechanism.

Name the product and site. Ask which exact filler is proposed at each location, what its FDA indication says, and whether the plan includes off-label placement. A clinician may consider a use outside labeling; the marketing copy should not call that particular use FDA approved.

Name the next decision. Ask how the provider will assess whether the first stage achieved the agreed goal before adding another site. A staged plan can make the visual contribution of each step clearer without promising a particular result.

Compare quotes by the proposed work, not a single unit price

A “per syringe” quote is incomplete unless it says which product, size, intended site, number of syringes, injector, follow-up, and what happens if a different amount is needed. One cheek-plus-fold proposal may use more product than a fold-only proposal because it treats more than one goal. The randomized trial’s combined arm used the most product; that is a trial-design fact, not a recommended purchase quantity.²

Treomark’s observed filler offers can show how local practices advertise prices, while a consultation supplies the personalized plan and total estimate. Compare proposals with the same requested endpoint and named products. Do not treat a lower per-syringe number as proof that two plans are clinically equivalent.

Bring a rest and smiling photograph that reflects your usual appearance, describe the specific fold or cheek change you want to discuss, and ask a dermal filler provider to identify product, placement, approved status, alternative, and complication response. That turns “smile lines” into a decision you can evaluate.